Evidence map›Paper›PMID 35719211›Full record

ArticleAntibody therapeutics2022

Evaluation of site-specific methylation of the CMV promoter and its role in CHO cell productivity of a recombinant monoclonal antibody.

Hussain Dahodwala, Sophia D Amenyah, Sarah Nicoletti, Matthew N Henry, Diane J Lees-Murdock, Susan T Sharfstein

Open access · goldAbstract read
In one paragraph

Article in Antibody therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. The 'Omics Revolution in CHO Biology: Roadmap to Improved CHO Productivity.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Hussain DahodwalaNational Institute for Innovation in Manufacturing Biopharmaceuticals, Newark, DE 19713, USA.
Sophia D AmenyahSchool of Biomedical Sciences, Ulster University, Coleraine, Co. Londonderry, BT52 1SA, Northern Ireland, UK.ORCID https://orcid.org/0000-0001-7785-4336
Sarah NicolettiCollege of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, NY 12203, USA.
Matthew N HenryAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St. Lucia, QLD 4072 , Australia.
Diane J Lees-MurdockSchool of Biomedical Sciences, Ulster University, Coleraine, Co. Londonderry, BT52 1SA, Northern Ireland, UK.ORCID https://orcid.org/0000-0002-1309-1605
Susan T SharfsteinCollege of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, NY 12203, USA.ORCID https://orcid.org/0000-0002-0908-4197
SUNY Polytechnic Institute · USUniversity of Ulster · GBNational Institute for Innovation in Manufacturing BiopharmaceuticalsThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously demonstrated that increased monoclonal antibody productivity in dihydrofolate reductase (DHFR)-amplified CHO cells correlates with phosphorylated transcription factor-cytomegalovirus (CMV) promoter interactions. In this article, we extend the characterization to include CMV promoter methylation and its influence on NFκB and CREB1 transcription factor binding to the CMV promoter in two families of DHFR-amplified CHO cell lines. CMV promoter methylation was determined using bisulfite sequencing. To overcome Sanger-sequencing limitations due to high CG bias and multiple transgenes copies, pyrosequencing was used to determine the frequency of methylated cytosines in regions proximal to and containing the NFκB and CREB1 transcription-factor consensus binding sites. Chromatin immunoprecipitation was performed to interrogate transcription factor-DNA interactions. Antibodies to CREB1 and NFκB were used to immunoprecipitate formaldehyde-crosslinked protein-DNA fractions, followed by reverse transcription quantitative real-time polymerase chain reaction to quantitate the number of copies of CMV-promoter DNA bound to the various transcription factors. The relative unmethylated fraction at the CREB1 and NFκB consensus binding sites determined by pyrosequencing was correlated with transcription factor binding as determined by chromatin immunoprecipitation. Azacytidine treatment reduced methylation in all treated samples, though not at all methylation sites, while increasing transcription. Distinct promoter methylation patterns arise upon clonal selection in different families of cell lines. In both cell line families, increased methylation was observed upon amplification. In one family, the NFκB binding-site methylation was accompanied by increased CREB1 interaction with the promoter. In the other cell line family, lower methylation frequency at the NFκB consensus binding site was accompanied by more NFκB recruitment to the promoter region.

Indexed as

azacytidineCMV promoterDNA methylationTranscriptional activation

Identifiers

PMID35719211
PMCPMC9199181
OpenAlexW4229369899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.